Atara Biotherapeutics
ATRA
121 hedge funds and large institutions have $1.68B invested in Atara Biotherapeutics in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 39 reducing their positions, and 13 closing their positions.
205% more call options, than puts
Call options by funds: $4.58M | Put options by funds: $1.5M
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
5% more funds holding
Funds holding: 115 → 121 (+6)
5% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 39
0.14% more ownership
Funds ownership: 4.09% → 4.23% (+0.14%)
13% less capital invested
Capital invested by funds: $1.92B → $1.68B (-$240M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.5M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$12.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.2M |
| 4 |
HCM
Highline Capital Management
New York
|
+$10.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$17.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$15.6M |
| 3 |
BM
Bridger Management
New York
|
-$9.37M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$4.13M |
| 5 |
Goldman Sachs
New York
|
-$3.22M |
ATRA Hedge Fund Activity: Q4 2018 in Review
121 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q4 2018, worth a combined $1.68B — down 13% from $1.92B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATRA positions and 13 closed out — a net gain of 7 holders — while 41 added to existing stakes and 39 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $20.5M. The largest seller was Assenagon Asset Management, exiting entirely with an estimated $17.2M sold.
- 121 institutional investors held Atara Biotherapeutics (ATRA) as of Q4 2018, up from 115 in Q3 2018.
- Funds reported $1.68B of Atara Biotherapeutics stock for Q4 2018, down 13% quarter-over-quarter.
- 20 funds opened new Atara Biotherapeutics positions in Q4 2018 and 13 closed out, a net change of +7 holders.
- The largest Atara Biotherapeutics buyer in Q4 2018 was Point72 Asset Management, an estimated $20.5M added.
- The largest Atara Biotherapeutics seller in Q4 2018 was Assenagon Asset Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q4 2018.